Ruixin Medical Secures Nearly RMB 100 Million Series D Funding Led by Guangzhou State-Owned Capital to Advance AI-Driven Cardiovascular Solutions

May 27, 2026 11:28 CST Updated 11:28

RaysightMed

Medical Imaging Product Developer

Recently, Shenzhen Raysightmed Co, Ltd. (hereinafter referred to as "RaysightMed") officially announced that it has successfully completed a Series D financing round of nearly RMB 100 million. This round of financing was coordinated by municipal and district-level state-owned capital investment platforms in Guangzhou, and was led by Guangzhou Biomedical and Health Industry Investment Co., Ltd. (hereinafter referred to as "Guangzhou Health Investment"), with GuangzhouYuefu FundManagement Co., Ltd. (hereinafter referred to as "Yuefu Fund") participated as a co-investor, successfully concluding the transaction in Yuexiu District, Guangzhou. The successful closure of this financing round reflects the high recognition from industrial investment funds regarding RaysightMed's core technologies, industrial value, and commercialization progress, and will inject strong momentum into the company's overall pipeline development, rapid business growth, and overseas market expansion. Concurrently, through this financing round, RaysightMed will deepen its forward-looking deployment of an AI-driven vascular interventional surgical robotic system, build an integrated AI and robotics diagnostic and therapeutic platform, capture the future track of minimally invasive and precision interventions, and establish robust dual barriers in both technology and commercialization.

Since its establishment,RaysightMedConsistently upholding the brand positioning——“Leader in Smart Integrated Solutions for Precise Cardiac Diagnosis and Treatment”, adhering to the mission and brand slogan “Safeguarding a Longer Rhythm of Life with Intelligent Technology”, focusing on the precise cardiovascular diagnosis and treatment sector, with hard-tech innovation as the core driving force, and integrating artificial intelligence,Hemodynamic Simulation, cutting-edge technologies such as surgical robots, has established an integrated intelligent diagnostic and therapeutic platform for cardiovascular and cerebrovascular diseases, spanning from preoperative diagnosis and intraoperative treatment to postoperative health management, developing a robust product portfolio that covers multiple clinical scenarios to fully address clinical diagnostic and therapeutic pain points. Meanwhile, RaysightMed has consecutively been awarded Arterial Network's “Future Healthcare Top 100” series Top 20 ranking signifies the industry's high recognition of the company's technological innovation, commercial deployment, and comprehensive capabilities in AI-powered cardiovascular precision diagnosis and treatment.

Among them, the core flagship productAngioQFALeveraging a cutting-edge technological architecture and precise clinical value, the system provides a one-stop assessment of coronary Fractional Flow Reserve (FFR) and the Index of Microcirculatory Resistance (IMR). It profoundly empowers precise intra-procedural evaluation and optimizes clinical decision-making, establishing itself as a benchmark solution for precision coronary diagnosis and treatment. Following its clinical deployment, it has garnered widespread recognition from industry experts in China, pioneering a new direction in intravascular functional diagnostics and therapy. Currently, RaysightMed has established a strategic global partnership with Blue Sail Medical, leading Chinese original medical products onto the international stage.

Another core product, Raysight FFR (CT-FFR), continues to advance its clinical implementation and expand its applications. As a benchmark in China's non-invasive coronary functional assessment sector, it consistently provides support for clinical diagnosis and treatment. Currently, RaysightMed and iFlytek Imaging are fully dedicated to driving the clinical adoption of the product while exploring new application scenarios. In addition, RaysightMed's newly launched Intracardiac Echocardiography (ICE) system focuses on precise intracardiac imaging diagnosis, further perfecting the comprehensive pre- and intraoperative diagnostic and therapeutic closed-loop workflow for electrophysiology and structural heart procedures. Meanwhile, by leveraging RaysightMed's extensive AI technology expertise, the system delivers clearer ICE imagery that better meets clinical demands.

In the future, guided by clinical needs, RaysightMed will continue to deepen its focus on the precision cardiovascular diagnosis and treatment sector, consolidate the market leadership of AngioQFA, and accelerate the commercialization of its product pipeline, including RaysightFFR, RaysightICE, and surgical robots. By driving the large-scale clinical application of innovative medical devices, the company will advance the quality enhancement and upgrading of cardiovascular disease diagnosis and treatment in China, ultimately benefiting a broader patient population.

RaysightMed CEO Zheng Lingxiao stated that he is highly gratified that the company's efforts have been recognized. Over the past few years, Chinese medical device enterprises have made substantial progress in exploring clinical needs, driving product innovation, and facilitating commercialization. Moving forward, RaysightMed will continue to advance, remain deeply rooted in China's clinical practice, and strive to grow into a global intelligent healthcare enterprise.

Feng Zhizhong, Deputy General Manager of Guangzhou Health Industry Investment, stated, "We are highly optimistic about RaysightMed's solid technological foundation and clinical product portfolio. We also highly recognize the team's capability and commitment to advancing the clinical implementation and commercialization of innovative technologies. Furthermore, we have even greater confidence in RaysightMed's strategic deployment in AI-integrated surgical robots. The fund will continue to support RaysightMed's sustained development."

Yang Qichao, head of Yuefu Fund Company, stated that RaysightMed's forward-looking strategic layout and investment in AI surgical robots closely align with the future development of the industry and the strategic planning of Yuexiu District, Guangzhou. Yuefu Fund is highly optimistic about this collaboration.